Cover Image
市場調查報告書

嗜鉻細胞瘤:開發平台分析

Pheochromocytoma - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 200475
出版日期 內容資訊 英文 66 Pages
訂單完成後即時交付
價格
Back to Top
嗜鉻細胞瘤:開發平台分析 Pheochromocytoma - Pipeline Review, H2 2016
出版日期: 2016年10月29日 內容資訊: 英文 66 Pages
簡介

本報告提供嗜鉻細胞瘤的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您企業和研究機關開發中的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊,再加上最新的新聞和發表等資訊。

嗜鉻細胞瘤是罕見的疾病,一般是非癌性(良性)腫,在腎上腺的細胞內相當發達。症狀有高血壓,強烈頭痛,身體顫抖,呼吸急促,便秘等。危險因子有多發性內分泌腫瘤症第二型、逢希伯-林道症候群(VHL)、神經性纖維瘤第一型等。

簡介

  • 調查範圍

嗜鉻細胞瘤 概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業開發中的治療藥

大學/機關研究中的治療藥

開發中產品概況

  • 臨床階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關研究中的產品

治療藥的開發企業

  • AstraZeneca PLC
  • Exelixis, Inc.
  • MediaPharma s.r.l.
  • Pfizer Inc.
  • Progenics Pharmaceuticals, Inc.

治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • cabozantinib s-malate
  • iobenguane sulfate I 131
  • MPHE-001B
  • S-43126
  • sunitinib malate
  • vandetanib

最近的開發平台趨勢

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8607IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pheochromocytoma - Pipeline Review, H2 2016, provides an overview of the Pheochromocytoma (Oncology) pipeline landscape.

Pheochromocytoma is a rare, usually non-cancerous (benign) tumor that develops in cells in the center of an adrenal gland. Symptoms include high blood pressure, severe headache, tremors, shortness of breath and constipation. Risk factors include multiple endocrine neoplasia type II (MEN), Von Hippel-Lindau disease (VHL) and neurofibromatosis 1 (NF1).

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pheochromocytoma - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Pheochromocytoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pheochromocytoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Pheochromocytoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Preclinical stages are 4 and 2 respectively for Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively for Pheochromocytoma.

Pheochromocytoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Pheochromocytoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Pheochromocytoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Pheochromocytoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Pheochromocytoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Pheochromocytoma (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Pheochromocytoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Pheochromocytoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Pheochromocytoma Overview
  • Therapeutics Development
    • Pipeline Products for Pheochromocytoma - Overview
    • Pipeline Products for Pheochromocytoma - Comparative Analysis
  • Pheochromocytoma - Therapeutics under Development by Companies
  • Pheochromocytoma - Therapeutics under Investigation by Universities/Institutes
  • Pheochromocytoma - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Pheochromocytoma - Products under Development by Companies
  • Pheochromocytoma - Products under Investigation by Universities/Institutes
  • Pheochromocytoma - Companies Involved in Therapeutics Development
    • Exelixis, Inc.
    • MediaPharma s.r.l.
    • Pfizer Inc.
    • Progenics Pharmaceuticals, Inc.
    • Valeant Pharmaceuticals International, Inc.
  • Pheochromocytoma - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • cabozantinib s-malate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • iobenguane sulfate I 131 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LMP-400 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • metyrosine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MPBF-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • S-43126 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sunitinib malate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Pheochromocytoma - Dormant Projects
  • Pheochromocytoma - Product Development Milestones
    • Featured News & Press Releases
      • Dec 03, 2015: Progenics Pharmaceuticals Achieves Target Enrollment in its Phase 2b Pivotal Trial of Azedra
      • Oct 12, 2015: Phase 2 Dosimetry Data for Progenics' AZEDRA Presented at EANM Congress 2015
      • Jul 28, 2015: Progenics Announces Breakthrough Therapy Designation for Azedra in Pheochromocytoma and Paraganglioma
      • Mar 02, 2015: Progenics Pharmaceuticals Announces Presentation at ENDO 2015
      • Jan 23, 2015: Progenics Pharmaceuticals Relaunches Pivotal Trial of AZEDRA in Pheochromocytoma
      • Sep 22, 2014: Progenics Pharmaceuticals Presents Long Term Follow-Up of Pivotal Phase 2 Trial of Azedra in Malignant Pheochromocytoma
      • Apr 01, 2014: Progenics Pharmaceuticals and Centre for Probe Development and Commercialization Announce Agreement to Manufacture Targeted Radiotherapeutic Candidate for Ultra-Orphan Indications
      • Nov 25, 2013: Progenics Pharmaceuticals Relaunching Registrational Trial of Azedra to Treat Pheochromocytomas
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Pheochromocytoma, H2 2016
  • Number of Products under Development for Pheochromocytoma - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Pheochromocytoma - Pipeline by Exelixis, Inc., H2 2016
  • Pheochromocytoma - Pipeline by MediaPharma s.r.l., H2 2016
  • Pheochromocytoma - Pipeline by Pfizer Inc., H2 2016
  • Pheochromocytoma - Pipeline by Progenics Pharmaceuticals, Inc., H2 2016
  • Pheochromocytoma - Pipeline by Valeant Pharmaceuticals International, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Pheochromocytoma - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Pheochromocytoma, H2 2016
  • Number of Products under Development for Pheochromocytoma - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top